ABSTRACT
Daunorubicin, thioguanine and cytosine arabinoside were administered from the 17th to 34th weeks of pregnancy in a 23-year-old patient with acute myeloid leukaemia. The patient went into remission of her leukaemia, and a normal male infant was born after labour was induced in the 40th week. This experience supports the view that modern regimens of anti-leukaemic drugs may be administered during the second and third trimesters of pregnancy without harmful effects on the foetus.
Subject(s)
Daunorubicin/pharmacology , Fetus/drug effects , Leukemia, Myeloid, Acute/complications , Pregnancy Complications, Hematologic , Adult , Cytosine/therapeutic use , Daunorubicin/therapeutic use , Female , Humans , Infant, Newborn , Labor, Induced , Leukemia, Myeloid, Acute/drug therapy , Male , Pregnancy , Pregnancy Trimester, Second , Pregnancy Trimester, Third , Thioguanine/therapeutic useABSTRACT
Monitoring to detect the "at risk" foetus has advanced dramatically in the last decade; clinical as well as more sophisticated methods have been discussed. Some of these are well within the scope of the general practitioner who has undergone further training in obstetrics. If all practitioners are aware of these advances, ready consultation for the continued monitoring of the foetus at risk will decrease the avoidable perinatal loss and quality of the neonate, which at the present time is showing virtually no improvement.